Full-Time

Senior Director

Translational Medicine

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS cancers

Biotechnology
Healthcare

Compensation Overview

$235k - $281kAnnually

Senior, Expert

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • A Ph.D. in cancer biology, cell/molecular biology, genomics or equivalent with 10+ years of industry experience.
  • 6+ years of experience in clinical biomarker development in oncology is required.
  • Broad knowledge and understanding of established and novel technologies employed in clinical diagnostic assays (e.g. NGS, IHC, PCR) are required.
  • Excellent scientific and business communication skills, strong interpersonal/collaboration skills and planning skills.
  • Ability to think critically and creatively and be able to work independently to determine appropriate resources for resolution of problems.
  • Ability to multi-task and thrive in a fast-paced innovative environment.
  • A great teammate, who listens effectively and invites response and discussion.
  • Commitment to Revolution Medicines’ Core Values: Tireless Commitment to Patients, Transformative Science, Exceptional Together, Total Integrity, Inclusiveness and Fairness.
Responsibilities
  • Lead strategic, translational thinking and contributions to early and late-stage clinical development plans.
  • Represent Translational Medicine function on cross-functional teams at program level.
  • Effectively collaborate with Clinical Development, Clinical Operations, Biostatistics, Biomarker Operations, and Regulatory on study design and protocol development.
  • Lead biomarker scientists in formulating clinical biomarker strategies and partner with clinical bioinformaticians in developing biomarker analysis plans, as well as effectively collaborate with TM subfunctions of Biomarker Operations, Clinical Bioinformatics, and Companion Diagnostics.
  • Collaborate with Clinical Development, Biostatistics, and Medical Affairs to develop plans for publication of clinical biomarker results.
  • Collaborate with Cancer Biology, Translational Research, and Cancer Immunology to accelerate forward and reverse translational research.
  • Keep abreast in new developments in RAS biology, predictive biomarkers, and novel molecular assays, and share knowledge with functional and cross-functional team members.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, which target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to concentrate their research and development efforts in this niche area. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

36%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for research and development.
  • Increased interest in targeted therapies boosts investment and partnership opportunities.
  • Shift towards personalized medicine aligns with their focus on genetic mutations.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and delay timelines.
  • EQRx's pricing model may conflict with Revolution Medicines' market strategies.
  • $600M public stock offering may dilute existing shareholder value.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive licensing with the University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?